Brief: Gland Pharma Says USFDA Concludes Inspection At Co’S Visakhapatnam Facilities
01/09/2026 12:43
BRIEF-Gland Pharma Says USFDA Concludes Inspection At Co’S Visakhapatnam Facilities Sept 1 (Reuters) - Gland Pharma Ltd GLAD.NS:
GLAND PHARMA - CONCLUSION OF USFDA INSPECTION AT CO’S VISAKHAPATNAM FACILITIES
GLAND PHARMA - USFDA INSPECTION CONCLUDED WITH ZERO OBSERVATIONS
Source text: ID:nBSE6405N7
Further company coverage: GLAD.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gland Pharma
See all newsIndia Stocks: Indian shares open higher as Fed-hike fears, oil prices ease; financials lead
India Stocks: Indian shares poised to rebound as Fed-hike fears, oil prices ease
Brief: Gland Pharma Approves $21 Million Investment In Gland Pharma Usa
Brief: Fosun Pharma Says Unit Sold Gland Pharma Shares for $294 Mln
India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant